Research News and Research

RSS

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced Calypso’s real-time tracking technology is included in 36 scientific presentations and posters at the 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), now underway at McCormick Place in Chicago.

3 Nov 2009

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

Schering-Plough Corporation today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support successful implementation of the projects in ten villages surrounding Bangalore and Pune, India.

3 Nov 2009

Half of American children including 90% black children will use food stamps, says study

Nearly half of American children - including 90 percent of black children and 90 percent of children who spend their childhoods in single-parent households - will eat meals paid for by food stamps at some point during childhood, reports a Cornell researcher.

3 Nov 2009

Challenges in global health: rising to meet them could save millions of lives, say experts

Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. The articles, by leading global health experts from around the world, show that although these challenges differ dramatically, rising to meet them could save millions of lives.

3 Nov 2009

Caliper Life Sciences presents the benefits of its LabChip GX platform

Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

PCNA launches "Family at Heart" educational campaign

Recent research indicates that despite decades of progress, fewer Americans are now considered "low risk" for heart disease compared to years past. Adding fuel to the fire, a new study is making headlines with the alarming statistic that 7 in 10 obese teens already have at least one risk factor for heart disease.

3 Nov 2009

Sexual relationships were significantly affected after a stroke, says study

Dr Assumpta Ryan and Hilary Thompson recently published findings from a study involving 16 married stroke survivors - nine males and seven females - aged between 33 and 78.

3 Nov 2009

Want to quit smoking? Try a nicotine patch plus a nicotine lozenge

In a comparison of five different smoking cessation medications, a nicotine patch plus a nicotine lozenge appears most effective at helping smokers quit, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Nov 2009

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

AMRI announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company will proceed into preclinical development. AMRI will receive a $750,000 payment from Bristol-Myers Squibb for the completion of this milestone, marking the fifth milestone payment in the ongoing research collaboration between the two companies.

3 Nov 2009

Not enough is being done to support patients suffering from tinnitus

As many as one in seven people will experience tinnitus, or ringing in their ears, at some time of their life, but not enough is being done to support patients who experience this distressing condition, according to an extensive research review in the November issue of the Journal of Clinical Nursing.

3 Nov 2009

AAPM Task Group issues new radiation guidelines for brachytherapy

Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient, according to a new guideline co-authored by Yan Yu, Ph.D., director of Medical Physics in the department of Radiation Oncology at Thomas Jefferson University.

3 Nov 2009

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

3 Nov 2009

No evidence found to link decreased physical activity and spike in obesity rates among U.S. adolescents

Decreased physical activity may have little to do with the recent spike in obesity rates among U.S. adolescents, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

3 Nov 2009

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference.

3 Nov 2009

Teva Pharmaceutical Industries net sales up 25%

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2009.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.

3 Nov 2009

Research News and Research

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

Half of American children including 90% black children will use food stamps, says study

Challenges in global health: rising to meet them could save millions of lives, say experts

Caliper Life Sciences presents the benefits of its LabChip GX platform

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

PCNA launches "Family at Heart" educational campaign

Sexual relationships were significantly affected after a stroke, says study

Want to quit smoking? Try a nicotine patch plus a nicotine lozenge

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

Not enough is being done to support patients suffering from tinnitus

AAPM Task Group issues new radiation guidelines for brachytherapy

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

No evidence found to link decreased physical activity and spike in obesity rates among U.S. adolescents

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

Teva Pharmaceutical Industries net sales up 25%

Phase 1 study of STX107 for Fragile X syndrome begins

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms